Diabetes medicine review found differing kidney, nerve and eye results
Randomized trials of non-insulin diabetes medicines reported differing effects across complication measures. Favorable kidney measurements did not establish broad protection, and comparator details were absent from the abstract.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review examined whether non-insulin diabetes medicines affect complications involving small blood vessels. Some drug families showed favorable kidney measurements, but nerve and eye results were less consistent. The abstract also flagged a possible increase in diabetic retinal disease with semaglutide. These findings do not establish a single medicine as best across complications.
The abstract gives no effect sizes, comparator details or follow-up durations. The authors describe the available results as conflicting or unclear, limiting assessment of the size and reliability of differences between medicines.
Kidney measurements need distinction
The review assessed estimated kidney filtration and urine albumin relative to creatinine, a urine protein measure. Findings differed across these measurements and drug families. Favorable changes in these indicators should not be restated as proof of fewer kidney-failure events.
Other complications differed
Evidence supporting several medicines used alone was sparse. Some treatments showed possible nerve benefits, while others did not demonstrate changes in nerve measurements. The reported semaglutide eye-risk signal came from a named trial, rather than a universal finding across drugs.
The original publication
The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials.
Wen S, Yuan Y, Li Y et al.
BMC Endocr Disord · 2025
- PubMed ID
- 40665260
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.